Leishmania parasites synthesize a range of mannosecontaining glycoconjugates thought to be essential for virulence in the mammalian host and sandfly vector. A prerequisite for the synthesis of these molecules is the availability of the activated mannose donor, GDP-Man, the product of the catalysis of mannose-1-phosphate and GTP by GDP-mannose pyrophosphorylase (GDP-MP). In contrast to the lethal phenotype in fungi, the deletion of the gene in Leishmania mexicana did not affect parasite viability but led to a total loss of virulence, making GDP-MP an ideal target for anti-Leishmania drug development. We show by immunofluorescence and subcellular fractionation that GDP-MP is a cytoplasmic protein, and we describe a colorimetric activity assay suitable for the high throughput screening of small molecule inhibitors. We expressed recombinant GDP-MP as a fusion with maltose-binding protein and separated the enzyme from maltose-binding protein by thrombin cleavage, ion-exchange, and size exclusion chromatography. Size exclusion chromatography and analytical ultracentrifugation studies demonstrate that GDP-MP self-associates to form an enzymatically active and stable hexamer. However, sedimentation studies show that the GDP-MP hexamer dissociates to trimers and monomers in a time-dependent manner, at low protein concentrations, at low ionic strength, and at alkaline pH. Circular dichroism spectroscopy reveals that GDP-MP is comprised of mixed ␣/ structure, similar to its closest related homologue, N-acetyl-glucoseamine-1-phosphate uridyltransferase (Glmu) from Streptococcus pneumoniae. Our studies provide insight into the structure of a novel target for the development of anti-Leishmania drugs.The eukaryotic protozoa of the genus Leishmania are the causative agents of several human diseases referred to as leishmaniases. Symptoms range from self-healing cutaneous lesions to the fatal visceral form of the disease. Leishmaniasis occurs in tropical and subtropical regions of the world, with an estimated 12 million people infected and 350 million at risk of infection (1, 2).Attempts to produce an effective vaccine have so far failed, and treatment of the disease in regions other than northeast India still relies primarily on the use of pentavalent antimonials, drugs first introduced in the 1930s (2, 3). Moreover, drug resistance has become an increasing problem in the treatment of leishmaniasis (4, 5). It is clear that there is an urgent need for new and specific drugs to combat the disease. With a view to developing such drugs, parasite-specific biochemical and biosynthetic pathways involved in virulence are beginning to be targeted (reviewed in Davis et al. (28)).Leishmania synthesize a number of unique mannose-containing glycoconjugates that are secreted or that form a thick glycocalyx on the surface of the parasite (6, 7). Several of the membrane-bound glycoconjugates such as lipophosphoglycan (LPG), 1 glycosylinositolphospholipids (GIPLs) (8, 9), and proteophosphoglycan (7, 10) are virulence factors mediating hostparas...